Figure 7. Enhanced uptake of FITC-OVA by BMDC induced by treatment with LT-IIa-B₅ is dependent on TLR2.

A. BMDC treated with PBS (untreated), 5 μg/ml of LT-IIa-B₅, or 1 μg/ml of LPS were co-incubated with 10 μg/ml or 20 μg/ml of an anti-TLR2 blocking mAb (α-TLR2). After 10 min, BMDC were incubated with FITC-OVA (0.2 mg/ml), washed with PBS, and stained for CD11c. CD11c-positive cells were measured for FITC fluorescence. Data are presented as the MFI. Error bars denote one standard deviation from the mean obtained from triplicate cultures. Key: ***, statistically different from the untreated group or, for the anti-TLR2-treated cells, statistically different from the LT-IIa-B₅-treated group (as denoted by the lines) (P<0.001); ns, not significant from the untreated group. B. BMDC derived from the bone marrow of wt C57Bl/6 mice or C57Bl/6(TLR2^-/-) mice treated with PBS (Untreated), 5 μg/ml of LT-IIa-B₅, or 1 μg/ml of LPS were incubated with FITC-OVA (0.2 mg/ml) for 10 min, washed with PBS, and stained for CD11c. Data are presented as the MFI with error bars denoting one standard deviation from the mean obtained from triplicate cultures. Key: +, TLR2-proficient BMDC; -, TLR2-deficient BMDC; +++, statistical difference from the matched (Untreated vs TLR2-deficient) control; ***, statistical difference between the wt and TLR2-deficient BMDC treated with LT-IIa-B₅ (as denoted by the lines); ns, not significant to the matched untreated control or, in the case of the LPS-treated cells, no significant difference between the TLR2-proficient and the TLR2-deficient BMDC.